Table 1.
Barriers to overcome by the 3G DDSs. (From reference [31]).
1. | Delivery of poorly soluble drugs |
Non-toxic excipients | |
2. | Peptide/protein/nucleic acid delivery |
Control of the initial burst release and subsequent release rate | |
Non-invasive delivery | |
In vitro-in vivo correlation | |
3. | Targeted drug delivery |
Tumor targeting in human | |
Overcoming blood-brain barrier | |
4. | Self-regulated drug delivery |
Functional in the body for extended period of time |